Home Stocks Cipla Ltd

Cipla Ltd

The live share price of Cipla Ltd (CIPLA) as on 08 Dec 10:21am is ₹1,219.1 from NSE/BSE.

CIPLA NSE

₹1,219.1 ▼-0.3% (-3.7)

As on Dec 08, 2023 03:51 PM IST

How do you feel today about Cipla Ltd?

Bearish or

Bullish

Bearish or

Bullish

Key Metrics

PE Ratio

28.59

PB Ratio

4.16

Dividend Yield

0.69%

Sector PB

5.11

Sector PE

44.48

Sector Div Yld

0.7%

Dividend Yield

Dividend per share for the most recent financial year divided by the close price

About

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Largecap, ₹98,722 Cr

Cipla Limited is a pharmaceutical company. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious diseases & critical care, malaria etc.

The following charts display the financial performance of the Cipla Ltd (CIPLA) stock, including the year-on-year Income Statement , Balance Sheet , Cash Flow Statement and Shareholding pattern.

Furthermore, under the Peers section, you can find stocks that are similar to Cipla Ltd (CIPLA), and their live stock price and performance at a glance. Click on any peer stock to navigate to that stock’s live price page.

✅ If you’re new to investing in the stock market, and/or are unsure about your investment options, you can explore smallcases.

A smallcase is a readymade stock/ETF portfolio (also known as a stock basket) that is based on an investment idea, theme or strategy. Examples of popular smallcases include All Weather Investing , Equity and Gold , Top 100 Stocks , Green Energy and Value & Momentum.

All smallcases are created and managed by SEBI-registered investment experts.

To invest in smallcases, all you need is a demat/trading account. You retain complete ownership of the smallcase’s constituent stocks or ETFs, as they are directly credited to your broking account. You can choose from over 500+ smallcases across 180+ smallcase managers to start your investment journey.

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Largecap, ₹98,722 Cr

Financials

Income Statement

(INR)		Y/Y Change
Revenue	23,228 Cr	+5.37%
Operating Expense	1,873 Cr	+60.18%
Net Income	2,801 Cr	+11.33%
Net Profit Margin	12.06%	+5.6%
Earning Per Share	34	+11.28%
EBITDA	5,320 Cr	+14.37%

Balance sheet

(INR)		Y/Y Change
Cash & short-term Inv	4,654 Cr	+12.88%
Total Assets	29,300 Cr	+9.1%
Total Liabilities	5,586 Cr	-2.67%
Total Equity	23,713 Cr	+12.29%
Shares Outstanding	80.72 Cr	+0.05%
Price to Book	3.07	-20.82%
Return on Assets	9.98%	+2.57%
Return on Capital	17.49 Cr	+2.58%

Cash Flows

(INR)		Y/Y Change
Net Income	2,801 Cr	+11.33%
Cash from Operations	3,237 Cr	-2.65%
Cash from Investing	-2,376 Cr	+27.86%
Cash from Financing	-958 Cr	-40.1%
Net Change in Cash	-96 Cr	-26.86%
Free Cash Flow	2,054 Cr	-21.72%

Shareholding Pattern

Total Promoter Holding

33.4%

Unpledged

Foreign Institutions

25.69%

Foreign Institutions

Retail & Others

16.78%

Retail & Others

Other Parties

Other Domestic Institutions

7.69%

Insurance Firms

Others

Mutual Funds

16.45%

Mutual Funds

Peers

SUNPHARMA

Sun Pharmaceutical Industries Ltd

PE Ratio

34.78

1Y Return

▲26%

DRREDDY

Dr Reddy's Laboratories Ltd

PE Ratio

18.92

1Y Return

▲32.31%

MANKIND

Mankind Pharma Ltd

PE Ratio

51.24

1Y Return

▲37.3%

TORNTPHARM

Torrent Pharmaceuticals Ltd

PE Ratio

52.94

1Y Return

▲26.44%

Latest News

Taking Stock: Sensex, Nifty take a break after 7-day run; mid, smallcaps outperform

2 days ago on Moneycontrol

Change since news ▼-1.15%

Top losers on the Nifty were Bharti Airtel, HUL, ONGC, Apollo Hospitals and Tata Steel, while gainers included Power Grid Corporation, Adani Ports, UltraTech Cement, Cipla and Grasim Industries

Top Nifty gainers and losers at mid-day: NTPC, Axis surge, Wipro, Cipla decline

1 week ago on Moneycontrol

Change since news ▼-0.56%

The Nifty zoomed to a new high and the Sensex traded over 500 points higher in the afternoon, About 2,044 shares advanced, 1,110 declined and 103 remained unchanged

Cipla EU acquires additional stake in JV with Cooper Pharma; shares rise

2 weeks ago on Moneycontrol

Change since news ▼-1.71%

Cipla EU acquired an additional 15.1 percent of Cipla Maroc SA, Morocco, which is a JV between Cooper Pharma and Cipla EU.

FAQs on Cipla Ltd

How to buy Cipla Ltd stocks?

You can easily buy the stocks/shares of Cipla Ltd (CIPLA) through either a broker or a financial institution by opening a Demat & Trading account online via smallcase.

What is the Share Price of Cipla Ltd?

The stock price of Cipla Ltd as on 08 Dec 2023 is ₹1,219.1

What is the 52-week High and Low of Cipla Ltd?

The 52-week high and low of Cipla Ltd (CIPLA) is ₹1,283.55 and ₹852.

What is the PE and PB ratio of Cipla Ltd?

The P/E (price-to-earnings) and P/B (price-to-book) ratios of Cipla Ltd are 28.59 and 4.16 respectively.

What are the peers or stocks similar to Cipla Ltd?

The peers or stocks similar to Cipla Ltd are Sun Pharmaceutical Industries Ltd, Dr Reddy's Laboratories Ltd, Mankind Pharma Ltd, Torrent Pharmaceuticals Ltd and many others. smallcase also offers over 200 readymade stock baskets managed by 180+ SEBI-registered investment experts. These stock portfolios are based on a theme, idea or strategy. You can use smallcase to start investing in diversified stock baskets.

Which sector does Cipla Ltd belong to?

Cipla Ltd (CIPLA) belongs to the Pharmaceuticals sector.

What is the Market Cap of Cipla Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cipla Ltd (CIPLA) is ₹98,722 Cr as of 08 Dec 2023

Can't decide whether or not to buy Cipla Ltd stocks? ⭐️

Worry no more! smallcase offers readymade stock baskets/portfolios that are based on an theme, idea or strategy. You can choose from more than 500+ stock portfolios managed by 180+ SEBI-registered investment experts.

Dislaimer: This platform is intended for informational purposes only and is not intended to provide investment advice. The stock prices displayed are delayed and may not reflect the most current market conditions. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. You can also consider consulting a financial advisor before making any investment decisions. Smallcase Technologies Private Limited shall not be responsible for any losses that may occur as a result of using this platform.